A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine

Inclusion Criteria:

• Have a diagnosis of migraine with or without aura as defined by the IHS ICHD-3guidelines (1.1 or 1.2 according to ICHD-3 [2018]), with a history of migraineheadaches of at least 6 months prior to screening.

Exclusion Criteria:

• Participants who are taking, or are expected to take, therapeutic antibodies duringthe course of the study (adalimumab, infliximab, trastuzumab, bevacizumab, etc.).Prior use of therapeutic antibodies is allowed if that use was more than 12 monthsprior to baseline.

• Known hypersensitivity to monoclonal antibodies or other therapeutic proteins, or togalcanezumab or its excipients.

• Current use or prior exposure to galcanezumab, another CGRP antibody, or CGRPreceptor antibody, including those who have previously completed or withdrawn fromthis study or any other study investigating a CGRP antibody.

• History of IHS ICHD-3 diagnosis of new daily persistent headache, cluster headacheor migraine subtypes including hemiplegic (sporadic or familial) migraine andmigraine with brainstem aura (previously basilar-type migraine).

• History of significant head or neck injury within 6 months prior to screening; ortraumatic head injury at any time that is associated with significant change in thequality or frequency of their headaches, including new onset of migraine followingtraumatic head injury.

• Participants with a known history of intracranial tumors or developmentalmalformations including Chiari malformations.